The accumulating evidence of tau pathology encompasses broad dysregulations at the genetic and molecular levels, in CNS tissue and associated biological fluids, and therefore argue in favor of the classification of HD as a secondary tauopathy. The gene discussed is MAPT; the disease is tauopathy.